Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hydroxycut Recall Eyed As Trigger For Closer Look At Supplement AERs

This article was originally published in The Tan Sheet

Executive Summary

The dietary supplement industry looks to FDA's Hydroxycut investigation for a sign on whether the agency will analyze adverse event reports more closely following a high-profile product recall
Advertisement

Related Content

U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales
U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales
Durbin Requests GAO Inquiry On Supplement Adverse Event Reports
FTC Raises Claim Substantiation Bar For Dietary Supplements In Settlements
FDA Suggests Supplement Firms Use MedDRA Internally For AER Data
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
Iovate intros new Hydroxycut formula
Sales & Earnings In Brief
Hydroxycut Recall Sheds Light On Pros And Cons Of AER System
Hydroxycut Recall Sheds Light On Pros And Cons Of AER System

Topics

Advertisement
UsernamePublicRestriction

Register

PS102920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel